Targeting IRAK4 disrupts inflammatory pathways and delays tumor development in chronic lymphocytic leukemia
Menée à l'aide de cellules mononucléées du sang périphérique prélevé sur des patients atteints d'une leucémie lymphoïde chronique ou sur des témoins en bonne santé et menée à l'aide de modèles murins, cette étude met en évidence l'intérêt de cibler la kinase IRAK4 pour perturber les voies de signalisation impliquées dans les processus inflammatoires et retarder le développement tumoral
Interleukin-1 receptor-associated kinase 4 (IRAK4) plays a critical role in Toll-like receptor (TLR) signal transduction and innate immune responses. Recruitment and subsequent activation of IRAK4 upon TLR stimulation is mediated by the myeloid differentiation primary response 88 (MYD88) adaptor protein. Around 3% of chronic lymphocytic leukemia (CLL) patients have activating mutations of MYD88, a driver mutation in this disease. Here, we studied the effects of TLR activation and the pharmacological inhibition of IRAK4 with ND2158, an IRAK4 competitive inhibitor, as a therapeutic approach in CLL. Our in vitro studies demonstrated that ND2158 preferentially killed CLL cells in a dose-dependent manner. We further observed a decrease in NF-κB and STAT3 signaling, cytokine secretion, proliferation and migration of primary CLL cells from MYD88-mutated and -unmutated cases. In the Eµ-TCL1 adoptive transfer mouse model of CLL, ND2158 delayed tumor progression and modulated the activity of myeloid and T cells. Our findings show the importance of TLR signaling in CLL development and suggest IRAK4 as a therapeutic target for this disease.